BioMérieux Reports Solid Third-Quarter 2025 Performance

bioMérieux announced a 7.3% organic sales growth in the first nine months of 2025, reaching €2,992 million. This growth aligns with the GO•28 strategic plan, driven by 10% growth in BIOFIRE® non-respiratory panels and a 114% surge in SPOTFIRE®. However, sales were impacted by a decline in China and in BIOFIRE® Respiratory Panels due to low epidemiological activity.

The company's Q3 organic growth stood at 3%, affected by a decrease in China and an 8% drop in BIOFIRE® Respiratory Panels. Excluding these factors, the performance reached 7.6%. For 2025, sales growth is projected between 5.5% and 6.5% at constant exchange rates, with an anticipated CEBIT growth between 12% and 18%.

CEO Pierre Boulud emphasized the ongoing expansion of the company's installed base, pointing to significant growth opportunities. Recent FDA clearance for BIOFIRE® SPOTFIRE® and the launch of the GENE-UP® PRO HRM highlight bioMérieux's continued innovation.